CAPTRUST Financial Advisors
LOGC

CAPTRUST Financial Advisors’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

CAPTRUST Financial Advisors’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-300
Closed – – 4560
2022
Q2 		$0 Hold
300
– – ﹤0.01% 5272
2022
Q1 		$0 Hold
300
– – ﹤0.01% 5265
2021
Q4 		$1K Hold
300
– – ﹤0.01% 4688
2021
Q3 		$1K Hold
300
– – ﹤0.01% 4537
2021
Q2 		$1K Buy
+300
New +$1.53K ﹤0.01% 4433

Other funds holding LOGC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CAPTRUST Financial Advisors's LOGC Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2022, closing a stake of 300 shares.

CAPTRUST Financial Advisors first reported a position in LOGC in Q2 2021 and held it in 5 quarters. The position peaked at $1K in Q4 2021. 39 funds tracked by Wall St. Rank hold LOGC as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 300 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's LogicBio Therapeutics, Inc. Common Stock position peaked at $1K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.